• Explore /
  • Poster
  • / Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).

Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).

Abstract Poster

Authors

null

Kamaneh Montazeri

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Kamaneh Montazeri , George Dranitsaris , Catherine Curran , Jonathan David Thomas , Matthew D. Ingham , Mark A. Preston , Graeme S. Steele , Kerry L. Kilbridge , Xiao X. Wei , Bradley Alexander McGregor , Matthew Mossanen , Guru Sonpavde

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Quality of Care/Quality Improvement

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 474)

Abstract #

474

Poster Bd #

G19

Abstract Disclosures

Similar Posters

First Author: Matt D. Galsky

First Author: Srikala S. Sridhar

First Author: Matthew R. Zibelman

First Author: Benjamin Miron